Logo image of PHN.MI

PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis

Europe - Euronext Milan - BIT:PHN - IT0005274094 - Common Stock

53.7 EUR
-0.3 (-0.56%)
Last: 12/23/2025, 7:00:00 PM
Fundamental Rating

7

Taking everything into account, PHN scores 7 out of 10 in our fundamental rating. PHN was compared to 15 industry peers in the Personal Care Products industry. PHN gets an excellent profitability rating and is at the same time showing great financial health properties. PHN is valued quite expensively, but it does show have an excellent growth rating. With these ratings, PHN could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year PHN was profitable.
In the past year PHN had a positive cash flow from operations.
Each year in the past 5 years PHN has been profitable.
PHN had a positive operating cash flow in each of the past 5 years.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

PHN's Return On Assets of 20.41% is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
The Return On Equity of PHN (38.54%) is better than 100.00% of its industry peers.
PHN has a Return On Invested Capital of 26.24%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PHN is significantly above the industry average of 11.99%.
The 3 year average ROIC (17.21%) for PHN is below the current ROIC(26.24%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 20.41%
ROE 38.54%
ROIC 26.24%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

Looking at the Profit Margin, with a value of 13.48%, PHN is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
PHN's Profit Margin has declined in the last couple of years.
PHN's Operating Margin of 21.87% is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of PHN has remained more or less at the same level.
PHN has a Gross Margin of 97.04%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
PHN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.87%
PM (TTM) 13.48%
GM 97.04%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

8

2. Health

2.1 Basic Checks

PHN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PHN has about the same amout of shares outstanding than it did 1 year ago.
PHN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for PHN has been reduced compared to a year ago.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

PHN has an Altman-Z score of 9.47. This indicates that PHN is financially healthy and has little risk of bankruptcy at the moment.
PHN has a better Altman-Z score (9.47) than 100.00% of its industry peers.
PHN has a debt to FCF ratio of 2.70. This is a good value and a sign of high solvency as PHN would need 2.70 years to pay back of all of its debts.
PHN has a Debt to FCF ratio of 2.70. This is comparable to the rest of the industry: PHN outperforms 60.00% of its industry peers.
PHN has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PHN (0.28) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 2.7
Altman-Z 9.47
ROIC/WACC3.34
WACC7.85%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

PHN has a Current Ratio of 2.06. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.06, PHN belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
PHN has a Quick Ratio of 1.75. This is a normal value and indicates that PHN is financially healthy and should not expect problems in meeting its short term obligations.
PHN has a Quick ratio of 1.75. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.75
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.20% over the past year.
PHN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.63% yearly.
Looking at the last year, PHN shows a quite strong growth in Revenue. The Revenue has grown by 15.06% in the last year.
PHN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.59% yearly.
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%

3.2 Future

Based on estimates for the next years, PHN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.13% on average per year.
Based on estimates for the next years, PHN will show a quite strong growth in Revenue. The Revenue will grow by 14.07% on average per year.
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y14.07%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

2

4. Valuation

4.1 Price/Earnings Ratio

PHN is valuated rather expensively with a Price/Earnings ratio of 21.92.
Compared to the rest of the industry, the Price/Earnings ratio of PHN indicates a somewhat cheap valuation: PHN is cheaper than 66.67% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.50, PHN is valued at the same level.
With a Price/Forward Earnings ratio of 21.99, PHN is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 66.67% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.93. PHN is around the same levels.
Industry RankSector Rank
PE 21.92
Fwd PE 21.99
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

PHN's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, PHN is valued a bit more expensive than 73.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 63.46
EV/EBITDA 12.21
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of PHN may justify a higher PE ratio.
PHN's earnings are expected to grow with 15.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.51
PEG (5Y)1.5
EPS Next 2Y13.31%
EPS Next 3Y15.13%

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 1.87%, PHN has a reasonable but not impressive dividend return.
PHN's Dividend Yield is comparable with the industry average which is at 2.15.
PHN's Dividend Yield is comparable with the S&P500 average which is at 1.87.
Industry RankSector Rank
Dividend Yield 1.87%

5.2 History

On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

PHN pays out 40.63% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of PHN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP40.63%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

PHARMANUTRA SPA

BIT:PHN (12/23/2025, 7:00:00 PM)

53.7

-0.3 (-0.56%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-10 2026-03-10/amc
Inst Owners17.42%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap519.82M
Revenue(TTM)175.08M
Net Income(TTM)23.61M
Analysts82.86
Price Target82.62 (53.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.87%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP40.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.72%
EPS NY rev (3m)-6.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 21.92
Fwd PE 21.99
P/S 2.97
P/FCF 63.46
P/OCF 42.18
P/B 8.49
P/tB 13.93
EV/EBITDA 12.21
EPS(TTM)2.45
EY4.56%
EPS(NY)2.44
Fwd EY4.55%
FCF(TTM)0.85
FCFY1.58%
OCF(TTM)1.27
OCFY2.37%
SpS18.09
BVpS6.33
TBVpS3.86
PEG (NY)3.51
PEG (5Y)1.5
Graham Number18.68
Profitability
Industry RankSector Rank
ROA 20.41%
ROE 38.54%
ROCE 45.24%
ROIC 26.24%
ROICexc 32.19%
ROICexgc 49.25%
OM 21.87%
PM (TTM) 13.48%
GM 97.04%
FCFM 4.68%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 2.7
Debt/EBITDA 0.4
Cap/Depr 97.13%
Cap/Sales 2.36%
Interest Coverage 250
Cash Conversion 28.97%
Profit Quality 34.7%
Current Ratio 2.06
Quick Ratio 1.75
Altman-Z 9.47
F-Score7
WACC7.85%
ROIC/WACC3.34
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y14.07%
EBIT growth 1Y14.83%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.16%
EBIT Next 3Y18.62%
EBIT Next 5Y9.97%
FCF growth 1Y144.25%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y38.33%
OCF growth 3Y0.14%
OCF growth 5Y11.34%

PHARMANUTRA SPA / PHN.MI FAQ

What is the fundamental rating for PHN stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.


What is the valuation status for PHN stock?

ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.


How profitable is PHARMANUTRA SPA (PHN.MI) stock?

PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.


Can you provide the financial health for PHN stock?

The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.


How sustainable is the dividend of PHARMANUTRA SPA (PHN.MI) stock?

The dividend rating of PHARMANUTRA SPA (PHN.MI) is 5 / 10 and the dividend payout ratio is 40.63%.